678 related articles for article (PubMed ID: 34391508)
1. Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis.
Zhou X; Yao Z; Bai H; Duan J; Wang Z; Wang X; Zhang X; Xu J; Fei K; Zhang Z; Tan F; Xue Q; Gao S; Gao Y; Wang J; He J
Lancet Oncol; 2021 Sep; 22(9):1265-1274. PubMed ID: 34391508
[TBL] [Abstract][Full Text] [Related]
2. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
Nishijima TF; Shachar SS; Nyrop KA; Muss HB
Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115
[TBL] [Abstract][Full Text] [Related]
3. Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.
Wang Y; Zhou S; Yang F; Qi X; Wang X; Guan X; Shen C; Duma N; Vera Aguilera J; Chintakuntlawar A; Price KA; Molina JR; Pagliaro LC; Halfdanarson TR; Grothey A; Markovic SN; Nowakowski GS; Ansell SM; Wang ML
JAMA Oncol; 2019 Jul; 5(7):1008-1019. PubMed ID: 31021376
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
[TBL] [Abstract][Full Text] [Related]
5. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
[TBL] [Abstract][Full Text] [Related]
6. Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis.
Mori K; Pradere B; Quhal F; Katayama S; Mostafaei H; Laukhtina E; Schuettfort VM; D'Andrea D; Egawa S; Bensalah K; Schmidinger M; Powles T; Shariat SF
Cancer Treat Rev; 2021 Sep; 99():102242. PubMed ID: 34153830
[TBL] [Abstract][Full Text] [Related]
7. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.
Duan J; Cui L; Zhao X; Bai H; Cai S; Wang G; Zhao Z; Zhao J; Chen S; Song J; Qi C; Wang Q; Huang M; Zhang Y; Huang D; Bai Y; Sun F; Lee JJ; Wang Z; Wang J
JAMA Oncol; 2020 Mar; 6(3):375-384. PubMed ID: 31876895
[TBL] [Abstract][Full Text] [Related]
8. Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens.
Yao J; Li M; Zhang H; Ge Y; Weygant N; An G
Int Immunopharmacol; 2020 Oct; 87():106770. PubMed ID: 32702598
[TBL] [Abstract][Full Text] [Related]
9. The Inconsistent and Inadequate Reporting Of Immune-Related Adverse Events in PD-1/PD-L1 Inhibitors: A Systematic Review of Randomized Controlled Clinical Trials.
Xie T; Zhang Z; Qi C; Lu M; Zhang X; Li J; Shen L; Peng Z
Oncologist; 2021 Dec; 26(12):e2239-e2246. PubMed ID: 34396642
[TBL] [Abstract][Full Text] [Related]
10. Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.
Khunger M; Rakshit S; Pasupuleti V; Hernandez AV; Mazzone P; Stevenson J; Pennell NA; Velcheti V
Chest; 2017 Aug; 152(2):271-281. PubMed ID: 28499515
[TBL] [Abstract][Full Text] [Related]
11. Toxicities associated with immune checkpoint inhibitors: a systematic study.
Kong X; Chen L; Su Z; Sullivan RJ; Blum SM; Qi Z; Liu Y; Huo Y; Fang Y; Zhang L; Gao J; Wang J
Int J Surg; 2023 Jun; 109(6):1753-1768. PubMed ID: 37132038
[TBL] [Abstract][Full Text] [Related]
12. Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer.
Shao J; Wang C; Ren P; Jiang Y; Tian P; Li W
Biosci Rep; 2020 May; 40(5):. PubMed ID: 32315071
[TBL] [Abstract][Full Text] [Related]
13. The Efficacy and Safety of PD-1/PD-L1 Inhibitors in Combination with Conventional Therapies for Advanced Solid Tumors: A Meta-Analysis.
Nie RC; Zhao CB; Xia XW; Luo YS; Wu T; Zhou ZW; Yuan SQ; Wang Y; Li YF
Biomed Res Int; 2020; 2020():5059079. PubMed ID: 32461994
[TBL] [Abstract][Full Text] [Related]
14. Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials.
Sonpavde GP; Grivas P; Lin Y; Hennessy D; Hunt JD
Future Oncol; 2021 Jul; 17(19):2545-2558. PubMed ID: 33783228
[No Abstract] [Full Text] [Related]
15. Immune-Related Neurological Toxicities of PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis.
Tian Y; Gao A; Wen Q; Wang S; Zhang S; Yang X; Su G; Sun Y
Front Immunol; 2020; 11():595655. PubMed ID: 33391266
[TBL] [Abstract][Full Text] [Related]
16. Effectivity and safety of PD-1/PD-L1 inhibitors for different level of PD-L1-positive, advanced NSCLC: A meta-analysis of 4939 patients from randomized controlled trials.
Shi Y; Duan J; Guan Q; Xue P; Zheng Y
Int Immunopharmacol; 2020 Jul; 84():106452. PubMed ID: 32339922
[TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials.
Luo W; Wang Z; Tian P; Li W
J Cancer Res Clin Oncol; 2018 Oct; 144(10):1851-1859. PubMed ID: 30019319
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular Toxicity With PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis.
Liu S; Gao W; Ning Y; Zou X; Zhang W; Zeng L; Liu J
Front Immunol; 2022; 13():908173. PubMed ID: 35880172
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant PD-1/PD-L1 Inhibitors for Resectable Head and Neck Cancer: A Systematic Review and Meta-analysis.
Masarwy R; Kampel L; Horowitz G; Gutfeld O; Muhanna N
JAMA Otolaryngol Head Neck Surg; 2021 Oct; 147(10):871-878. PubMed ID: 34473219
[TBL] [Abstract][Full Text] [Related]
20. The incidence and relative risk of PD-1/PD-L1 inhibitors-related colitis in non-small cell lung cancer: A meta-analysis of randomized controlled trials.
Lin LL; Lin GF; Luo Q; Chen XQ
Int Immunopharmacol; 2019 Dec; 77():105975. PubMed ID: 31704288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
